Molecular design of new antibiotics and antibiotic adjuvants against MCR strains

Patent metadata

Field	Value
Publication number	US-12473250-B2
Application number	US-202017612013-A
Country	US
Kind code	B2
Filing date	May 18, 2020
Priority date	May 17, 2019
Publication date	Nov 18, 2025
Grant date	Nov 18, 2025

Abstract

The present invention relates to a compound comprising a hydrophobic moiety, a linker and N-containing moiety. The present invention also relates to the method of synthesizing the compound and the use of the compound as an antibiotic or an adjuvant for an antibiotic.

First claim

The invention claimed is:

1 . A compound having the following formula (I):
Z 1 -L 1 -A-L 2 -Z 2   formula (I)
wherein A is selected from the group consisting of

and any mixture thereof;
L 1 and L 2 are independently a substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, alkoxycarbonyl, alkanoyloxy, carboxamido, ether, —(O—CH 2 —CH 2 —O) n —, L 3 , or any combination thereof, wherein L 3 has the following structure:

wherein n is an integer from 1 to 10 and R 4 is an amino; and
Z 1 and Z 2 independently have the following structure:

R 1 and R 2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aminoalkyl, guanidine, substituted or unsubstituted guanidylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, amino acid or peptide, or R 1 and R 2 are taken together to form a saturated or unsaturated, substituted or unsubstituted heterocyclic ring; and
R 3 is absent or hydrogen, or substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aminoalkyl, guanidine, substituted or unsubstituted guanidylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, amino acid or peptide,
wherein when R 3 is present, the nitrogen atom is a cationic quaternary nitrogen,
wherein the broken bond represents where the structure attaches to the remainder of formula (I);
wherein each substituted alkyl, substituted alkenyl, substituted alkynyl, substituted aminoalkyl, substituted guanidylalkyl, substituted aryl, substituted heteroaryl, substituted heteroarylalkyl, substituted heterocyclic ring is substituted with one or more groups independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkylalkenyl, heterocycloalkyl, cycloalkylheteroalkyl, cycloalkyloxy, cycloalkenyloxy, cycloamino, halo, carboxyl, haloalkyl, haloalkenyl, haloalkynyl, alkynyloxy, heteroalkyloxy, hydroxyl, hydroxyalkyl, alkoxy, alkenyloxy, nitro, amino, alkylamino, dialkylamino, alkenylamine, aminoalkyl, alkynylamino, acyl, alkyloxy, alkyloxyalkyl, alkyloxyaryl, alkyloxycarbonyl, alkyloxycycloalkyl, alkyloxyheteroaryl, alkyloxyheterocycloalkyl, acylamino, alkylsulfonyloxy, heterocyclic, heterocycloalkenyl, heterocycloalkyl, heterocycloalkylalkyl, heterocycloalkylalkenyl, heterocycloalkylheteroalkyl, heterocycloalkyloxy, heterocycloalkenyloxy, heterocycloamino, haloheterocycloalkyl, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, sulfinyl, sulfinylamino, sulfonyl, sulfonylamino, aryl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroalkyl, heteroarylamino, heteroaryloxy, arylalkenyl, arylalkyl, aryloxy, arylsulfonyl, cyano, cyanate, isocyanate, —C(O)NH(alkyl), and —C(O)N(alkyl) 2 .

2 . The compound according to claim 1 , wherein R 1 , R 2 and R 3 independently comprise a functional group selected from the group consisting of amine, guanidine, pyrrolidine, pyrrole, imidazolidine, pyrazolidine, imidazole, pyrazole, triazole, piperidine, pyridine, piperazine, diazine, hydroxamic acid, hydrazine, N-hydroxyurea, squaric acid, carbamolyphosphonate, oxazoline, pyrimidinetrione, 1-hydroxy-2(1H)-pyridinone (1,2-HOPO) and any combination thereof.

3 . The compound according to claim 1 , wherein L 1 and L 2 are independently selected from the group consisting of —(CH 2 ) 4 —, amide,

and any combination thereof.

4 . The compound according to claim 1 , wherein the compound of formula (I) has the following structure:

5 . The compound according to claim 1 , wherein each N-containing moiety is independently chelated to zinc.

6 . A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt or hydrate thereof, in association with a pharmaceutically acceptable carrier.

7 . A process for preparing a compound according to claim 1 , comprising the steps of:
1) Contacting a hydrophobic moiety selected from the group consisting of:

with a linker selected from the group consisting of 1,4-dibromobutane, 1,3-diiodobutane, ethyl iodoacetate, hydroxybenzotriazole, 1,2-dibromoethane, 1,3-dibromopropane, methyl iodoacetate, methyl bromoacetate, 1,4-diiodobutane and any combination thereof, under reaction conditions; and
2) contacting the linker with an N-containing moiety selected from the group consisting of dipicolylamine, cyclen, 1,8-dimethyl,1,4,8,11-tetracyclotetradecane, diethylamine, —NH[(CH 2 ) 3 N(CH 3 )] 2 , —NH 2 (CH 2 ) 3 N(CH 3 ) 2 , 5-bromopentyltrimethylammonium bromide, 3-bromopentyl trimethylammonium bromide, 4-bromobutyl triethylammonium bromide, 3-(4-Bromobutyl)-1-methylimidazole bromide, 1-(4-Bromobutyl)pyridine bromide, 1-(4-Bromobutyl)pyridine bromide and any combination thereof, under reaction conditions.

8 . The process according to claim 7 , wherein a covalent bond is formed between the hydrophobic moiety and the N-containing moiety or the hydrophobic moiety and the linker or the linker and the N-containing moiety.

9 . The process according to claim 7 , comprising the step of adding zinc after the N-containing moiety is covalently bonded to the linker or hydrophobic moiety.

10 . The process according to claim 7 , wherein the contacting is done in a solvent selected from the group consisting of acetone, methanol, ethanol, propanol, butanol, N,N-dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dichloromethane, pyridine, water and any mixture thereof; or wherein the contacting step is performed at a temperature in the range of about 21° C. to about 160° C.; or wherein the contacting step is performed for a duration in the range of about 2 hours to about 36 hours.

11 . A method for killing or inhibiting the growth of a microorganism in vitro, comprising the step of contacting the microorganism with the compound according to claim 1 .

12 . A method for treating a bacterial infection, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 , or wherein the method further comprises the step of administering a therapeutic amount of colistin in conjunction with the compound of claim 1 .

Assignees

• Singapore Health Serv Pte Ltd
• Agency Science Tech & Res
• Tan Tock Seng Hospital Pte Ltd

Inventors

• Aung Thet Tun
• Li Jianguo
• Koh Jun Jie
• Rajamani Lakshminarayanan
• Beuerman Roger
• Tan Tiang Hwee Donald
• Periayah Mercy Halleluyah
• Verma Chandra Shekhar
• Chen Swaine
• Barkham Timothy

Classifications

• C07C279/14

  being further substituted by carboxyl groups · CPC title

• C07D213/04

  having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom · CPC title

• C07D233/60

  with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms · CPC title

• C07C217/22

  by carbon atoms having at least two bonds to oxygen atoms · CPC title

• A61P31/04

  Antibacterial agents · CPC title